The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.

Many organizations have yet to reach a level of maturity in their mobile programs to reflect the critical role devices play.

Orchard Therapeutics, a Kyowa Kirin company, today announced presentations from seven abstracts from across its hematopoietic stem cell (HSC) gene therapy portfolio will be featured at the 21st Annual ...

To learn more about gene therapy for ARVC and participation in the RIDGE-1 study, please visit ARVCstudies.com or ClinicalTrials.gov (NCT06228924). Tenaya is also conducting a global natural history ...